ADMA Biologics (ADMA) vs Novavax (NVAX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Novavax (NVAX) has outperformed ADMA Biologics (ADMA) over the past year, gaining 21.7% versus a loss of 27.5%. Over five years, ADMA leads with a +821.8% price change compared with -93.1% for NVAX. ADMA Biologics is the larger company by market cap ($2.32 billion vs $1.81 billion), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADMA | NVAX |
|---|---|---|
| Share price | $10.37 | $10.96 |
| Market cap | $2.32B | $1.81B |
| 1-day change | +2.27% | -2.32% |
| YTD return | -44.41% | +66.96% |
| 1-year return | -27.52% | +21.69% |
| 5-year return | +821.82% | -93.07% |
| P/E ratio (TTM) | 14.81 | — |
| Forward P/E | 10.99 | — |
| EPS (TTM) | $0.70 | $-1.58 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $20.46 | $13.39 |
| 52-week low | $7.21 | $6.20 |
| Distance from 52-week high | -49.31% | -18.15% |
| Analyst consensus | none | buy |
| Avg. price target upside | +63.93% | +27.74% |
| Average volume | 2.63M | 5.16M |
| Shares outstanding | 223.98M | 164.95M |
| Employees | 640 | 749 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NVAX has outperformed ADMA by 49.2 percentage points over the past year.
About ADMA Biologics
ADMA stock →ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 640 employees
About Novavax
NVAX stock →Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 749 employees
ADMA vs NVAX FAQ
Which is bigger, ADMA Biologics or Novavax?
ADMA Biologics (ADMA) is larger, with a market capitalization of $2.32B compared with $1.81B for Novavax (NVAX).
Which stock has performed better over the past year, ADMA or NVAX?
NVAX returned +21.69% over the past 12 months, compared with -27.52% for ADMA (price return, excluding dividends). Past performance does not predict future results.
Are ADMA Biologics and Novavax in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.